Guidance predicting therapy response in IgAN is currently lacking although controlled studies have yielded reductions in proteinuria. To serve this urgent need, the project aims at developing an urine-proteomic biomarker-based algorithm that predicts immunosuppressive drug response in IgAN, personalizing intervention and significantly improving patient management.
This project was funded by the ERA-NET PerMed programme (Ref. No. ERAPERMED2018-217) co-funded by the European Commission and the national funding agencies.